At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 90 enrolled
Drug / intervention
Trabectedin +1 moredrug
Likely dose
Trabectedin 1.5 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Trabectedin for Recurrent Grade II or III Meningioma: a Randomized Phase II Study of the EORTC Brain Tumor Group
European Organisation for Research and Treatment of Cancer - EORTC·interventional·Posted Sep 9, 2014·Updated Jul 10, 2025
In Brief
A Phase 2 clinical trial evaluating Trabectedin and Local standard of care for Recurrent High Grade Meningioma. Completed, enrolled 90 participants across 47 sites in 10 countries.
Detailed Summary
The aim of this study is to collect data on activity, toxicity and quality of life of trabectedin therapy in patients with recurrent high-grade meningioma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent High Grade Meningioma
CountriesAustria, Belgium, France, Germany, Italy, Netherlands, Norway, Spain, Switzerland, United Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedSep 2014
Enrollment StartJul 2015
Primary CompletionJul 2017
Study CompletionJan 2019
TodayJul 2026
First PostedSep 9, 2014
Enrollment StartJul 1, 2015
Primary CompletionJul 1, 2017
Study CompletionJan 16, 2019
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 11.8 years ago
Interventions
Trabectedindrug
Trabectedin will be given as a 24-hour infusion every 3 weeks at a starting dose of 1.5 mg/m2 body surface area (BSA), until one of the treatment withdrawal criteria has been met.
Local standard of careother
Left to the discretion of the investigator